S&P 500   5,011.12 (-0.22%)
DOW   37,775.38 (+0.06%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
S&P 500   5,011.12 (-0.22%)
DOW   37,775.38 (+0.06%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
S&P 500   5,011.12 (-0.22%)
DOW   37,775.38 (+0.06%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
S&P 500   5,011.12 (-0.22%)
DOW   37,775.38 (+0.06%)
QQQ   423.41 (-0.57%)
AAPL   167.04 (-0.57%)
MSFT   404.27 (-1.84%)
META   501.80 (+1.54%)
GOOGL   156.01 (+0.35%)
AMZN   179.22 (-1.14%)
TSLA   149.93 (-3.55%)
NVDA   846.71 (+0.76%)
AMD   155.08 (+0.69%)
NIO   4.00 (+2.30%)
BABA   68.88 (+0.09%)
T   16.33 (+1.30%)
F   12.06 (+0.17%)
MU   111.93 (-3.78%)
GE   152.94 (-1.75%)
CGC   7.83 (+20.65%)
DIS   112.43 (-0.45%)
AMC   2.92 (-2.01%)
PFE   25.39 (-0.12%)
PYPL   62.10 (-1.83%)
XOM   118.52 (-0.09%)
LON:BXP

Beximco Pharmaceuticals (BXP) Share Price, News & Analysis

GBX 36.60
+0.10 (+0.27%)
(As of 01:40 PM ET)
Today's Range
36.40
36.60
50-Day Range
36.22
41
52-Week Range
33.30
45
Volume
34,232 shs
Average Volume
45,618 shs
Market Capitalization
£163.28 million
P/E Ratio
457.50
Dividend Yield
8.20%
Price Target
N/A
BXP stock logo

About Beximco Pharmaceuticals Stock (LON:BXP)

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.

BXP Stock Price History

BXP Stock News Headlines

Beximco Pharma Share Chat
Beximco Pharmaceuticals Ltd DR
Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report
Eager to enhance your investment strategies with foresight? Dive into our intriguing report: "The Top 3 AI Stocks for 2024." Gain profound insights and uncover the secrets with just a click! Why This Report Is Your Gateway to Success: * Expertly Curated: Delve into the AI stocks handpicked by our market analysts for 2024's success story. * In-Depth Analysis: Dive deep into comprehensive profiles and explore each top stock. (**By clicking the link you are subscribing to The Wealthiest Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.)
Beximco Pharmaceuticals Ltd. (BXPq)
BXP.L - Beximco Pharmaceuticals Limited
Beximco Pharmaceuticals
Beximco Pharmaceuticals Ltd.
Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report
Eager to enhance your investment strategies with foresight? Dive into our intriguing report: "The Top 3 AI Stocks for 2024." Gain profound insights and uncover the secrets with just a click! Why This Report Is Your Gateway to Success: * Expertly Curated: Delve into the AI stocks handpicked by our market analysts for 2024's success story. * In-Depth Analysis: Dive deep into comprehensive profiles and explore each top stock. (**By clicking the link you are subscribing to The Wealthiest Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.)
Beximco Pharmaceuticals Ltd (BXPH)
Beximco Pharmaceuticals Ltd. GDR
See More Headlines
Receive BXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beximco Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
5,700
Year Founded
N/A

Profitability

Net Income
£4.92 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£41.65 billion

Miscellaneous

Free Float
N/A
Market Cap
£163.28 million
Optionable
Not Optionable
Beta
0.64
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Mohammad Ali Nawaz
    Chief Financial Officer
  • Mr. S. M. Rabbur Reza
    Chief Operating Officer
  • Mr. Jamal Ahmed Choudhury
    Director of Accounts & Finance
  • Mr. Rizvi Ul Kabir
    Director of Marketing
  • Mr. M. A. Arshad Bhuiyan
    General Manager of Human Resources
  • Mr. Zakaria Seraj Chowdhury
    Head of Distribution Services & Director of International Marketing
  • Mr. Mohammad Asad Ullah FCS
    Company Secretary & Executive Director

BXP Stock Analysis - Frequently Asked Questions

How have BXP shares performed in 2024?

Beximco Pharmaceuticals' stock was trading at GBX 41.50 at the start of the year. Since then, BXP stock has decreased by 11.8% and is now trading at GBX 36.60.
View the best growth stocks for 2024 here
.

Is Beximco Pharmaceuticals a good dividend stock?

Beximco Pharmaceuticals (LON:BXP) pays an annual dividend of GBX 3 per share and currently has a dividend yield of 6.45%. BXP has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 3,750.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

How do I buy shares of Beximco Pharmaceuticals?

Shares of BXP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:BXP) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners